We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Mutated Signaling Pathway Triggers Lung Cancer Metastasis

By LabMedica International staff writers
Posted on 14 Jul 2009
Cancer researchers have found that in addition to the mutations that cause lung cancer, these cells require another mutation to metastasize and spread to other tissues.

Lung cancers (adenocarcinomas) commonly result from mutations in the KRAS and EGFR genes. More...
Yet, cancer cells with only these mutations do not usually spread beyond the lungs.

To determine what genetic signals would be required to drive metastasis in lung tumors investigators at Memorial Sloan-Kettering Cancer Center (New York, NY, USA) employed bioinformatic techniques to screen numerous lung tumor samples. They reported in the July 2, 2009, online edition of the journal Cell that the WNT cell-signaling pathway - a common cause of colon cancer when mutated - was the only one of six pathways tested that was hyperactive in lung tumors that went on to metastasize but was normal in those that did not spread.

The WNT pathway targets the HOXB9 and LEF1 genes, which have been identified as mediators of chemotactic invasion and colony outgrowth.

"Mutations that activate the WNT pathway are a common cause of colon cancer, but lung tumors are initiated by mutations in other genes, so we were surprised that a hyperactive WNT pathway would be responsible for metastasis in lung cancer," said senior author Dr. Joan Massagué, professor of cell biology and genetics at Memorial Sloan-Kettering Cancer Center. "Our findings suggest that using treatments that target the WNT pathway may help prevent lung cancer from repeatedly seeding itself throughout the vital organs of patients at risk for metastasis."

Related Links:

Memorial Sloan-Kettering Cancer Center


Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Melanoma Panel
UltraSEEK Melanoma Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.